ダモラ・セラピューティクス
Galecto, Inc.
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -20.94 | $0 | -$21M |
| 2025 Q4 | -151.27 | $0 | $566,000 |
| 2025 Q3 | -2.36 | $0 | — |
| 2025 Q2 | -2.60 | $0 | — |
| 2025 Q1 | -1.92 | $0 | — |
| 2024 Q4 | -5.22 | $0 | — |
| 2024 Q3 |
| -3.39 |
| $0 |
| — |
| 2024 Q2 | -4.92 | $0 | -$4M |